As of 2024-12-11, the Intrinsic Value of Xvivo Perfusion AB (XVIVO.ST) is
5.59 SEK. This XVIVO.ST valuation is based on the model Discounted Cash Flows (Growth Exit 10Y).
With the current market price of 452.50 SEK, the upside of Xvivo Perfusion AB is
-98.80%.
The range of the Intrinsic Value is (1.50) - 104.66 SEK
XVIVO.ST Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(989.64) - (73.07) |
(140.97) |
-131.2% |
| DCF (Growth 10y) |
(1.50) - 104.66 |
5.59 |
-98.8% |
| DCF (EBITDA 5y) |
223.43 - 418.70 |
322.50 |
-28.7% |
| DCF (EBITDA 10y) |
488.04 - 1,062.00 |
758.58 |
67.6% |
| Fair Value |
32.42 - 32.42 |
32.42 |
-92.83% |
| P/E |
98.50 - 237.99 |
166.52 |
-63.2% |
| EV/EBITDA |
64.60 - 217.79 |
136.20 |
-69.9% |
| EPV |
(2.94) - (12.60) |
(7.77) |
-101.7% |
| DDM - Stable |
80.14 - 1,284.37 |
682.26 |
50.8% |
| DDM - Multi |
152.12 - 1,930.19 |
284.15 |
-37.2% |
XVIVO.ST Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
14,253.52 |
| Beta |
1.43 |
| Outstanding shares (mil) |
31.50 |
| Enterprise Value (mil) |
13,828.12 |
| Market risk premium |
5.10% |
| Cost of Equity |
7.06% |
| Cost of Debt |
5.00% |
| WACC |
7.05% |